VK2735

Category: Dual GIP/GLP-1 Agonist

An investigational dual GLP-1 and GIP receptor agonist developed by Viking Therapeutics. Currently in Phase 3 clinical trials (VANQUISH program), VK2735 has demonstrated superior weight loss efficacy compared to placebo and is available in both subcutaneous injectable and oral formulations.

Half-Life: 168 hours

Common Dosage: 2.5mg

Benefits

  • Superior weight loss (up to 14.7% in Phase 2 trials)
  • Once-weekly convenient dosing
  • Dual GIP/GLP-1 mechanism for broader metabolic effects
  • Reduced cardiovascular risk markers
  • Improved insulin sensitivity and blood glucose control
  • Available in injectable and oral tablet forms

Side Effects

  • Nausea (especially during titration)
  • Vomiting
  • Diarrhea
  • Constipation
  • Decreased appetite
  • Injection site reactions (injectable form)
  • Fatigue